Clinical Trial: Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448727) titled 'Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT' on Feb. 12.

Brief Summary: This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.

Study Start Date: Nov. 20, 2024

Study Type: OBSERVATIONAL

Condition: Head & Neck Cancer Head & Neck Squamous Cell Carcinoma

Recruitment Status: RECRUITI...